Photo from sukruyazar.com
Jul 20, 2024, 10:37
Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer
Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:
”ANTHER Trial Results: Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer. At a 10.3-year follow-up, dose-dense treatment showed:
- Better recurrence-free survival (HR 0.80; P = 0.030).
- Better event-free survival (HR 0.78; P = 0.009).
- Improved distant disease-free survival (HR 0.79; P = 0.030).
- There was no significant difference in overall survival (HR 0.82; P = 0.109).
Dose-dense regimens significantly improve breast cancer-free survival and disease-free survival compared to standard chemotherapy.”
Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, Jonas Bergh.
Source: Ivan R. Gonzalez/X
adjuvant chemotherapy
Alexios Matikas
Anne Andersson
Breast Cancer
cancer
Günther G. Steger
Hemming Johansson
Iván R. González
Jonas Bergh
Mats Hellström
Michael Gnant
Michael Untch
OncoDaily
Oncology
Per Malmström
Richard Greil
Sabine Schmatloch
Sibylle Loibl
Theodoros Foukakis
Tommy Fornander
Volker Möbus
Yvonne Brandberg
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19